ElecTrip uses eco-friendly Teslas to shuttle business people to and fro across the state. Courtesy of Electrip

A Texas startup shuffling business men and women across the state in style has created an elevated road trip experience for its customers.

Founded in 2018 and based in Austin, ElecTrip aims to add luxury and convenience to regional commutes between major Texas cities by providing transportation in Teslas equipped with WiFi, complimentary snacks, and professional drivers.

Mandeep Patel, a University of Texas at Austin student, had the idea for the company just about a year ago while completing an internship. Patel had the company up and running just a few months later.

Patel serves as founder and CEO, along with his classmate and co-founder, Eliott Lee, who is COO. Lee tells InnovationMap that he and Patel had gotten tired of the stress of airport travel, the restrictive schedule of buses, and the soul-draining fatigue of driving. ElecTrip's no-compromise solution is cost effective, comfortable, and carbon neutral.

"One thing we really pride ourselves on is being sustainable, energy-efficient, and having no emissions," Lee says.

ElecTrip offers door-to-door service for their customers, who can customize pickup and drop-off locations in any major Texas city. The company has eight routes between Houston, Austin, Dallas, and San Antonio, but customers can book a custom route within a 300-mile radius of those cities. Prices range from $249.99 to $429.99, but customers can opt to share rides to cut down on cost, with cars seating three to five riders.

"We emphasize on B2B, geared more towards businesses," says Lee, explaining that customers can customize their trip with food and beverage requests.

The company offers three different Tesla models: Tesla Model S, Tesla Model X, and Tesla Model 3, each offering a specific number of passenger seats, luggage capacity, and mileage range.

"The main reason why we chose Tesla is because of the supercharger network," says Lee in referring to Tesla's 1,422 Supercharger Stations throughout the United States.

Clients don't have to worry about the charging process, Lee says. The company plans the trips around these charging stations, which are free to any Tesla user.

ElecTrip is less than a year old and has already coordinated hundreds of rides, according to the website. While starting the company while still juggling classes — Lee expects to graduate from UT in 2020, while Patel is graduating this year — Lee says being a student-run startup has its perks.

"We find a lot of funding in startup competitions that only students have access to," said Lee.

Additional initial funding for the company came out of Patel's savings account, Lee says. ElecTrip owns one Tesla and rents out additional vehicles to cover the demand of rides. Lee explains that renting vehicles instead of owning them would cut back on the company's real estate while providing additional income for Tesla owners that aren't using their cars.

Patel and Lee are the only two full-time employees at ElecTrip, as all drivers work on a contract-basis. Lee tells InnovationMap that in the future, ElecTrip will focus on business partnerships.

"A lot of these other services are geared towards consumers," says Lee. "We hope to be geared toward mainly towards businesses in the long run."

ElecTrip is gearing up for growing its partnerships with local small businesses in Austin and Houston to provide food and drink products for rides.

"It is something we're looking at targeting in the next one or two months," says Lee.

Mandeep Patel (left) and Eliott Lee are the co-founders of ElecTrip, a travel company that uses Teslas across Texas.Courtesy of ElecTrip

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.